Omnicell (OMCL) Cash from Financing Activities (2010 - 2026)
Omnicell's (OMCL) quarterly Cash from Financing Activities came in at -$23.4 million in Q2 2026, down 103.81% year-over-year from $613.5 million in Q2 2025, and down 1077.62% quarter-over-quarter from $2.4 million in Q1 2026.
Analysis
Omnicell (OMCL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Omnicell (OMCL) has reported Cash from Financing Activities for 17 consecutive years, with -$23.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 103.81% year-over-year to -$23.4 million in Q2 2026; TTM through Jun 2026 was -$231.9 million, a 2.7% increase from a year earlier, with the FY2025 full-year figure at -$218.3 million, up 7.33% from the prior year.
- Cash from Financing Activities was -$23.4 million for Q2 2026 at Omnicell, down from $2.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $13.1 million in Q4 2023 and troughed at -$234.4 million in Q4 2024.
- A 5-year average of -$26.2 million and a median of $3.2 million in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 348.14% in 2023 and tumbled 6289.67% in 2025, its largest moves.
- Over 5 years, Cash from Financing Activities stood at $3.6 million in 2022, then jumped by 268.61% to $13.1 million in 2023, then sank by 1885.45% to -$234.4 million in 2024, then soared by 103.88% to $9.1 million in 2025, then sank by 357.01% to -$23.4 million in 2026.
- The last three Cash from Financing Activities figures came in at -$23.4 million (Q2 2026), $2.4 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | -263.16 Mn |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | -23.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.38 Mn |
| Mar 31, 2026 | 2.39 Mn |
| Dec 31, 2025 | 9.10 Mn |
| Sep 30, 2025 | -219.98 Mn |
| Jun 30, 2025 | -11.47 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | -234.43 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | -16.63 Mn |
| Mar 31, 2024 | 11.93 Mn |
| Dec 31, 2023 | 13.13 Mn |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 3.60 Mn |
| Mar 31, 2023 | 3.86 Mn |
| Dec 31, 2022 | 3.56 Mn |
| Sep 30, 2022 | 9.06 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | -32.12 Mn |
| Dec 31, 2021 | 6.67 Mn |
| Sep 30, 2021 | 18.28 Mn |